U.S. Health Secretary Robert F. Kennedy Jr.'s recent dismissal of all 17 members of the CDC's Advisory Committee on Immunization Practices (ACIP) has triggered a strong backlash from vaccine experts. The ousted panelists warn that the abrupt shakeup may undermine public health, reduce access to lifesaving vaccines, and increase the risk of preventable disease outbreaks.
Kennedy, a longtime vaccine skeptic, replaced the committee with eight new appointees, some of whom have publicly questioned vaccine safety. The decision was made just two days after the firings on June 9, 2025. In a joint article published in the Journal of the American Medical Association (JAMA), the former ACIP members expressed alarm over what they described as a destabilizing and unjustified overhaul.
They argue that the move, along with cuts to CDC immunization staff, weakens the national vaccine program and threatens decades of progress. “These decisions, made without clear rationale, may roll back the achievements of U.S. immunization policy,” the experts wrote. They emphasized the potential risk to public trust and the safety of families across the country.
Kennedy claimed the firings were necessary to eliminate alleged conflicts of interest among the previous panel members, many of whom were appointed during the Biden administration. However, he provided no evidence of specific misconduct or bias.
Health professionals and scientists warn that politicizing vaccine oversight could erode confidence in health authorities and negatively impact vaccine uptake. The Department of Health and Human Services has not yet responded to media inquiries regarding the controversy.
Kennedy’s sweeping changes mark a significant shift in U.S. health policy and come amid growing concerns over misinformation and vaccine hesitancy.


California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Pentagon Ends Military Education Programs With Harvard University
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Trump Family Files $10 Billion Lawsuit Over IRS Tax Disclosure
Trump Signs “America First Arms Transfer Strategy” to Prioritize U.S. Weapons Sales
U.S. Lawmakers to Review Unredacted Jeffrey Epstein DOJ Files Starting Monday
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
Trump Allegedly Sought Airport, Penn Station Renaming in Exchange for Hudson River Tunnel Funding
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 



